Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5

[1]  C. Mackay.  CCL3L1 dose and HIV-1 susceptibility. , 2005, Trends in molecular medicine.

[2]  B. Rovin,et al.  The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .

[3]  M. Oppermann,et al.  Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent. , 2004, Molecular biology of the cell.

[4]  M. Ng,et al.  A novel CCR5 mutation selectively affects immunoreactivity and fusogenic property of the HIV co-receptor , 2004, AIDS.

[5]  W. Modi,et al.  Functional redundancy of the human CCL4 and CCL4L1 chemokine genes. , 2004, Biochemical and biophysical research communications.

[6]  M. Oppermann,et al.  pH‐Independent Endocytic Cycling of the Chemokine Receptor CCR5 , 2004, Traffic.

[7]  G. Ahlenstiel,et al.  CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response? , 2004, The Journal of antimicrobial chemotherapy.

[8]  D. Duffy,et al.  CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. , 2004, Genes and immunity.

[9]  B. Olde,et al.  Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4 , 2003, AIDS.

[10]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[11]  G. Dubyak,et al.  Essential role for Ca2+ in regulation of IL-1beta secretion by P2X7 nucleotide receptor in monocytes, macrophages, and HEK-293 cells. , 2003, American journal of physiology. Cell physiology.

[12]  Thomas P. Sakmar,et al.  Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry , 2003, Journal of Virology.

[13]  D. Taub,et al.  MIP-1α and MIP-1β differentially mediate mucosal and systemic adaptive immunity , 2003 .

[14]  M. Oppermann,et al.  Analysis of Ligand-stimulated CC Chemokine Receptor 5 (CCR5) Phosphorylation in Intact Cells Using Phosphosite-specific Antibodies* , 2003, The Journal of Biological Chemistry.

[15]  V. Robert-Hebmann,et al.  Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. , 2003, Blood.

[16]  D. Taub,et al.  MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. , 2003, Blood.

[17]  M. Paterlini,et al.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. , 2002, Biophysical journal.

[18]  M. Alizon,et al.  Rescue of HIV-1 Receptor Function through Cooperation between Different Forms of the CCR5 Chemokine Receptor* , 2002, The Journal of Biological Chemistry.

[19]  T. Hope,et al.  Association of Chemokine-mediated Block to HIV Entry with Coreceptor Internalization* , 2002, The Journal of Biological Chemistry.

[20]  J. Christensen,et al.  The role of CC chemokine receptor 5 in antiviral immunity. , 2002, Blood.

[21]  P. Strange,et al.  Pathways for internalization and recycling of the chemokine receptor CCR5. , 2002, Blood.

[22]  D. Weissman,et al.  A Membrane-proximal Basic Domain and Cysteine Cluster in the C-terminal Tail of CCR5 Constitute a Bipartite Motif Critical for Cell Surface Expression* , 2001, The Journal of Biological Chemistry.

[23]  Martin Oppermann,et al.  Characterization of Sequence Determinants within the Carboxyl-terminal Domain of Chemokine Receptor CCR5 That Regulate Signaling and Receptor Internalization* , 2001, The Journal of Biological Chemistry.

[24]  Dominique Schols,et al.  Diverging binding capacities of natural LD78β isoforms of macrophage inflammatory protein‐1α to the CC chemokine receptors 1, 3 and 5 affect their anti‐HIV‐1 activity and chemotactic potencies for neutrophils and eosinophils , 2001, European journal of immunology.

[25]  M. Oppermann,et al.  Polymorphism of CC chemokine receptors CCR2 and CCR5 in Crohn's disease. , 2001, Immunology letters.

[26]  M. Hammer,et al.  Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Yuetsu Tanaka,et al.  Naturally Occurring Deletional Mutation in the C-Terminal Cytoplasmic Tail of CCR5 Affects Surface Trafficking of CCR5 , 2001, Journal of Virology.

[28]  B. Kwon,et al.  The seventh transmembrane domain of cc chemokine receptor 5 is critical for MIP-1beta binding and receptor activation: role of MET 287. , 2001, Biochemical and biophysical research communications.

[29]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[30]  R. Detels,et al.  Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study , 2000, AIDS.

[31]  V. Rivera,et al.  Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. , 2000, Brain : a journal of neurology.

[32]  R. Doms,et al.  Multiple nonfunctional alleles of CCR5 are frequent in various human populations. , 2000, Blood.

[33]  K. Welsh,et al.  Correspondence and requests for reprints should be addressed to Dr. Martin , 2022 .

[34]  Atsushi Mizoguchi,et al.  Mice with a Selective Deletion of the CC Chemokine Receptors 5 or 2 Are Protected from Dextran Sodium Sulfate-Mediated Colitis: Lack of CC Chemokine Receptor 5 Expression Results in a NK1.1+ Lymphocyte-Associated Th2-Type Immune Response in the Intestine1 , 2000, The Journal of Immunology.

[35]  N. Maeda,et al.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. , 2000, The American journal of pathology.

[36]  C. Broder,et al.  N-Linked Glycosylation of CXCR4 Masks Coreceptor Function for CCR5-Dependent Human Immunodeficiency Virus Type 1 Isolates , 2000, Journal of Virology.

[37]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[38]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[39]  Finn Sellebjerg,et al.  CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis , 2000, Journal of Neuroimmunology.

[40]  J. Haines,et al.  CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. , 2000, Immunogenetics.

[41]  C. V. Jensen,et al.  CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. , 2000, Journal of neuroimmunology.

[42]  J. Haines,et al.  CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis , 2000, Immunogenetics.

[43]  J. Goedert,et al.  Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. , 1999, Cancer research.

[44]  G Vassart,et al.  Extracellular Cysteines of CCR5 Are Required for Chemokine Binding, but Dispensable for HIV-1 Coreceptor Activity* , 1999, The Journal of Biological Chemistry.

[45]  A. Maynard,et al.  Naturally Occurring CCR5 Extracellular and Transmembrane Domain Variants Affect HIV-1 Co-receptor and Ligand Binding Function* , 1999, The Journal of Biological Chemistry.

[46]  J. Gómez-Reino,et al.  Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. , 1999, Arthritis and rheumatism.

[47]  J. Goedert,et al.  Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. , 1999, Blood.

[48]  J. Sodroski,et al.  CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. , 1998, Cellular immunology.

[49]  H. Marquart,et al.  CC chemokine receptor 5 polymorphism in rheumatoid arthritis. , 1998, The Journal of rheumatology.

[50]  N. Tarasova,et al.  Small molecule inhibitor of HIV‐1 cell fusion blocks chemokine receptor‐mediated function , 1998, Journal of leukocyte biology.

[51]  D. Littman.  Chemokine Receptors: Keys to AIDS Pathogenesis? , 1998, Cell.

[52]  N. Taylor,et al.  Macrophage inflammatory protein-1β induces migration and activation of human thymocytes , 1998 .

[53]  John P. Moore,et al.  Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage- and Dualtropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[54]  S. O’Brien,et al.  C-C chemokines, pivotal in protection against HIV type 1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  W. Gong,et al.  Monocyte Chemotactic Protein-2 Activates CCR5 and Blocks CD4/CCR5-mediated HIV-1 Entry/Replication* , 1998, The Journal of Biological Chemistry.

[56]  William C. Olson,et al.  Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry , 1998, Journal of Virology.

[57]  M. Carrington,et al.  Novel alleles of the chemokine-receptor gene CCR5. , 1997, American journal of human genetics.

[58]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[59]  S. Ullrich,et al.  STRL22 is a receptor for the CC chemokine MIP-3alpha. , 1997, Biochemical and biophysical research communications.

[60]  M. Metzker,et al.  The extent of genetic variation in the CCR5 gene , 1997, Nature Genetics.

[61]  D. Weissman,et al.  Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical Phenotypes, Defined Racial Background, and Quantified Risk , 1997, Molecular medicine.

[62]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[63]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[64]  P. Gray,et al.  Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for RANTES, MIP-1β, and MIP-1α* , 1996, The Journal of Biological Chemistry.

[65]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[66]  W. Farrar,et al.  Structural domains of interleukin-2 receptor beta critical for signal transduction: kinase association and nuclear complex-formation. , 1995, The Biochemical journal.

[67]  Jerome A. Zack,et al.  HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.